In a phase 2, multicenter, double-blind, parallel-group clinical trial, the golimumab treatment promoted an increase in insulin production and a decrease in exogenous insulin use in children and young adults with newly diagnosed T1D [188]. Here, INS is linked to type 1 diabetes mellitus.